Sunitinib: The first to arrive at first-line metastatic renal cell carcinoma

Advances in Therapy

Volumn 29, Issue 3, 2012, Pages 202-217

  Vázquez, Sergio ^a   León, Luis ^b   Fernández, Ovidio ^c   Lázaro, Martín ^d   Grande, Enrique ^e   Aparicio, Luis ^f  

^a HOSPITAL UNIVERSITARIO LUCUS AUGUSTI   (Spain)

^b University Hospital of Santiago de Compostela   (Spain)

^c Hospital Universitario de Ourense   (Spain)

^d Hospital Universitario de Vigo   (Spain)

^e HOSPITAL RAMÓN Y CAJAL   (Spain)

^f UNIVERSITY OF A CORUÑA   (Spain)

Author keywords

renal cell carcinoma; sunitinib; tyrosine kinase inhibitors

Indexed keywords

ABC TRANSPORTER; ALPHA INTERFERON; BEVACIZUMAB; CYTOCHROME P450 3A4; EVEROLIMUS; N DEETHYLSUNITINIB; PAZOPANIB; PLACEBO; PLATELET DERIVED GROWTH FACTOR; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; SUNITINIB; TEMSIROLIMUS; THYROTROPIN; VASCULOTROPIN; VASCULOTROPIN RECEPTOR; VON HIPPEL LINDAU PROTEIN;

ABDOMINAL PAIN; ABNORMAL LABORATORY RESULT; ACTIVE TRANSPORT; ADVANCED CANCER; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ALOPECIA; AMYLASE BLOOD LEVEL; ANEMIA; ANOREXIA; ANTIANGIOGENIC ACTIVITY; AREA UNDER THE CURVE; ARTERY OCCLUSION; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; BILIRUBIN BLOOD LEVEL; BLOATING; BLOOD TOXICITY; CANCER INHIBITION; CARDIOTOXICITY; CHEMOTHERAPY INDUCED EMESIS; COGNITIVE DEFECT; CONSTIPATION; CREATININE BLOOD LEVEL; DEPRESSION; DERMATITIS; DIARRHEA; DISTRIBUTION VOLUME; DIZZINESS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE REGIMEN; DRUG ELIMINATION; DRUG ERUPTION; DRUG FEVER; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DYSGEUSIA; DYSPEPSIA; DYSPHAGIA; DYSPNEA; EDEMA; ELECTROCARDIOGRAM; ENZYME INHIBITION; FATIGUE; FLATULENCE; FLU LIKE SYNDROME; FOOD INTAKE; GASTROINTESTINAL STROMAL TUMOR; GASTROINTESTINAL TOXICITY; GENE; GLUCOSE BLOOD LEVEL; HAND FOOT SYNDROME; HEART ARRHYTHMIA; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE CONDUCTION DISTURBANCE; HEARTBURN; HUMAN; HYPERTENSION; HYPOTHYROIDISM; KIDNEY CARCINOMA; KIDNEY DYSFUNCTION; LEUKOPENIA; LIPID BLOOD LEVEL; LIVER DYSFUNCTION; LYMPHOCYTOPENIA; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; METASTASIS; MOUTH PAIN; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MUSCLE WEAKNESS; MYALGIA; NAUSEA; NEUROENDOCRINE CARCINOMA; NEUROENDOCRINE TUMOR; NEUTROPENIA; OVERALL SURVIVAL; PALM AND SOLE ACRAL ERYTHEMA; PANCREAS TUMOR; PERIORBITAL EDEMA; PHARMACODYNAMICS; PHOSPHATE BLOOD LEVEL; PR INTERVAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; PRURITUS; QRS COMPLEX; QT PROLONGATION; RECOMMENDED DRUG DOSE; REPEATED DRUG DOSE; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; SKIN DISCOLORATION; SKIN EDEMA; SKIN TOXICITY; ST SEGMENT DEPRESSION; ST SEGMENT ELEVATION; STOMATITIS; T WAVE; THROMBOCYTOPENIA; THYROTROPIN BLOOD LEVEL; TIME TO MAXIMUM PLASMA CONCENTRATION; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; URIC ACID BLOOD LEVEL; VON HIPPEL LINDAU GENE; XEROSIS;

ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; HUMANS; INDOLES; KIDNEY NEOPLASMS; NEOPLASM METASTASIS; PYRROLES;

EID: 84858701414     PISSN: 0741238X     EISSN: 18658652     Source Type: Journal    
DOI: 10.1007/s12325-011-0099-9     Document Type: Review

References (37)

1. Motzer RJ, Bander NH, Nanus DM. Renal-cell carcinoma. N Engl J Med. 1996;335:865-875.
2. Motzer RJ, Hutson TE, Tomczak P, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol. 2009;27:3584-3590.
3. Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med. 2003;349:427-434. (Pubitemid 36910021)
4. Mendel DB, Laird AD, Xin X, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res. 2003;9:327-337. (Pubitemid 36109749)
5. Goodman VL, Rock EP, Dagher R, et al. Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma. Clin Cancer Res. 2007;13:1367-1373. (Pubitemid 46450424)
6. Faivre S, Demetri G, Sargent W, Raymond E. Molecular basis for sunitinib efficacy and future clinical development. Nat Rev Drug Discov 2007;6:734-745. (Pubitemid 47338181)
7. Abrams TJ, Lee LB, Murray LJ, Pryer NK, Cherrington JM. SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther. 2003;2:471-478.
8. Bello CL, Sherman L, Zhou J, et al. Effect of food on the pharmacokinetics of sunitinib malate (SU11248), a multi-targeted receptor tyrosine kinase inhibitor: results from a phase I study in healthy subjects. Anticancer Drugs. 2006;17:353-358.
9. Houk BE, Bello CL, Poland B, Rosen LS, Demetri GD, Motzer RJ. Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis. Cancer Chemother Pharmacol. 2010l;66:357-371.
10. Motzer RJ, Rini BI, Bukowski RM, et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA. 2006;295:2516-2524. (Pubitemid 43854967)
11. Gore ME, Szczylik C, Porta C, et al. Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. Lancet Oncol. 2009;10:757-763.
12. Escudier B, Pluzanska A, Koralewski P et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet. 2007;370:2103-2111. (Pubitemid 350296300)
13. Rini BI, Halabi S, Rosenberg JE, et al. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol. 2008;26:5422-5428.
14. Rini BI, Halabi S, Rosenberg JE, et al. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol. 2010;28:2137-2143.
15. Sternberg CN, Davis ID, Mardiak J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010;28:1061-1068.
16. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007;356:2271-2281. (Pubitemid 46849157)
17. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356:125-134. (Pubitemid 46089673)
18. Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008;372:449-456.
19. GlaxoSmithKline. Pazopanib Versus Sunitinib in the Treatment of Locally Advanced and/or Metastatic Renal Cell Carcinoma (COMPARZ). Available at: http://clinicaltrials.gov/ct2/show/NCT00720941. Accessed November 14, 2011.
20. Demetri GD, van Oosterom AT, Garrett CR, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet. 2006;368:1329-1338. (Pubitemid 44528723)
21. Houk BE, Bello CL, Kang D, Amantea M. A population pharmacokinetic meta-analysis of sunitinib malate (SU11248) and its primary metabolite (SU12662) in healthy volunteers and oncology patients. Clin Cancer Res. 2009;15:2497-2506.
22. Motzer JR, Hutson TE, Olsen MR, et al. Randomized phase II multicenter study of the efficacy and safety of sunitinib on the 4/2 versus continuous dosing schedule as first-line therapy of metastatic renal cell carcinoma: Renal EFFECT trial. J Clin Oncol. 2011;29. Abstract LBA308.
23. van der Veldt AA, Eechoute K, Gelderblom H, et al. Genetic polymorphisms associated with a prolonged progression-free survival in patients with metastatic renal cell cancer treated with sunitinib. Clin Cancer Res. 2011;17:620-629.
24. Faivre S, Delbaldo C, Vera K, et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol. 2006;24:25-35. (Pubitemid 46630490)
25. Zhu X, Stergiopoulos K, Wu S. Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: systematic review and metaanalysis. Acta Oncol. 2009;48:9-17.
26. Schmidinger M, Zielinski CC, Vogl UM, et al. Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2008;26:5204-5212.
27. Robert C, Soria JC, Spatz A, et al. Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol. 2005;6:491-500. (Pubitemid 40903630)
28. Tsai KY, Yang CH, Kuo TT, Hong HS, Chang JW. Hand-foot syndrome and seborrheic dermatitislike rash induced by sunitinib in a patient with advanced renal cell carcinoma. J Clin Oncol. 2006;24:5786-5788. (Pubitemid 46631323)
29. Rosenbaum SE, Wu S, Newman MA, West DP, Kuzel T, Lacouture ME. Dermatological reactions to the multitargeted tyrosine kinase inhibitor sunitinib. Support Care Cancer. 2008;16:557-566.
30. Wolter P, Stefan C, Decallonne B, et al. The clinical implications of sunitinib-induced hypothyroidism: a prospective evaluation. Br J Cancer. 2008;99:448-454.
31. Mannavola D, Coco P, Vannucchi G, et al. A novel tyrosine-kinase selective inhibitor, sunitinib, induces transient hypothyroidism by blocking iodine uptake. J Clin Endocrinol Metab. 2007;92:3531-3534. (Pubitemid 47435331)
32. Illouz F, Laboureau-Soares S, Dubois S, Rohmer V, Rodien P. Tyrosine kinase inhibitors and modifications of thyroid function tests: a review. Eur J Endocrinol. 2009;160:331-336.
33. Rini BI, Tamaskar I, Shaheen P, et al. Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst. 2007;99:81-83.
34. Rini BI, Escudier B, Tomczak P, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet. 2011;378:1931-1939.
35. Molina AM, Feldman DR, Ginsberg MS, et al. Phase II trial of sunitinib in patients with metastatic nonclear cell renal cell carcinoma. Invest New Drugs. 2012;30:335-340.
36. Choueiri TK, Plantade A, Elson P, et al. Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. J Clin Oncol. 2008;26:127-131.
37. Motzer RJ, Escudier B, Oudard S, et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer. 2010;116:4256-4265.